FDA Approves Johnson & Johnson's Oral Psoriasis Pill, Challenging Top Injectables

The U.S. Food and Drug Administration has approved Johnson & Johnson’s once-daily oral psoriasis pill, marking a major regulatory and commercial milestone. The drug positions itself as the first oral therapy to directly compete with leading injectable treatments like Tremfya and Skyrizi.

• FDA approved Johnson & Johnson's once-daily oral psoriasis pill
• First oral treatment to rival injectable biologics like Tremfya and Skyrizi
• J&J's drug directly competes with high-margin injectable therapies
• Impacts competitive landscape for VRTX, GSK, and PFE in dermatology
• Approval supports J&J’s pharmaceutical segment expansion
• No specific sales or market share figures cited in announcement